ログイン
言語:

WEKO3

  • トップ
  • コミュニティ
  • ランキング
AND
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "b326bbd0-ea5e-44fa-b158-844c58bd9eda"}, "_deposit": {"id": "23126", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "23126"}, "status": "published"}, "_oai": {"id": "oai:nagoya.repo.nii.ac.jp:00023126"}, "item_10_biblio_info_6": {"attribute_name": "\u66f8\u8a8c\u60c5\u5831", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2016-08", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "8", "bibliographicPageEnd": "409", "bibliographicPageStart": "401", "bibliographicVolumeNumber": "28", "bibliographic_titles": [{"bibliographic_title": "International Immunology"}]}]}, "item_10_description_4": {"attribute_name": "\u6284\u9332", "attribute_value_mlt": [{"subitem_description": "CD4+ regulatory T cells (Tregs) expressing the transcription factor FoxP3 are highly immune suppressive and play central roles in the maintenance of self-tolerance and immune homeostasis, yet in malignant tumors they promote tumor progression by suppressing effective antitumor immunity. Indeed, higher infiltration by Tregs is observed in tumor tissues, and their depletion augments antitumor immune responses in animal models. Additionally, increased numbers of Tregs and, in particular, decreased ratios of CD8+ T cells to Tregs among tumor-infiltrating lymphocytes are correlated with poor prognosis in various types of human cancers. The recent success of cancer immunotherapy represented by immune checkpoint blockade has provided a new insight in cancer treatment, yet more than half of the treated patients did not experience clinical benefits. Identifying biomarkers that predict clinical responses and developing novel immunotherapies are therefore urgently required. Cancer patients whose tumors contain a large number of neoantigens stemming from gene mutations, which have not been previously recognized by the immune system, provoke strong antitumor T-cell responses associated with clinical responses following immune checkpoint blockade, depending on the resistance to Treg-mediated suppression. Thus, integration of a strategy restricting Treg-mediated immune suppression may expand the therapeutic spectrum of cancer immunotherapy towards patients with a lower number of neoantigens. In this review, we address the current understanding of Treg-mediated immune suppressive mechanisms in cancer, the involvement of Tregs in cancer immunotherapy, and strategies for effective and tolerable Treg-targeted therapy.", "subitem_description_type": "Abstract"}]}, "item_10_identifier_60": {"attribute_name": "URI", "attribute_value_mlt": [{"subitem_identifier_type": "DOI", "subitem_identifier_uri": "http://doi.org/10.1093/intimm/dxw025"}, {"subitem_identifier_type": "HDL", "subitem_identifier_uri": "http://hdl.handle.net/2237/25320"}]}, "item_10_publisher_32": {"attribute_name": "\u51fa\u7248\u8005", "attribute_value_mlt": [{"subitem_publisher": "Oxford University Press"}]}, "item_10_rights_12": {"attribute_name": "\u6a29\u5229", "attribute_value_mlt": [{"subitem_rights": "This is a pre-copyedited, author-produced version of an article accepted for publication in [International Immunology] following peer review. The version of record [International Immunology. v.28, n.8, 2016, p.401-409] is available online at: http://doi.org/10.1093/intimm/dxw025."}]}, "item_10_select_15": {"attribute_name": "\u8457\u8005\u7248\u30d5\u30e9\u30b0", "attribute_value_mlt": [{"subitem_select_item": "author"}]}, "item_10_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0953-8178", "subitem_source_identifier_type": "ISSN"}]}, "item_creator": {"attribute_name": "\u8457\u8005", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Takeuchi, Yoshiko"}], "nameIdentifiers": [{"nameIdentifier": "68545", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nishikawa, Hiroyoshi"}], "nameIdentifiers": [{"nameIdentifier": "68546", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "\u30d5\u30a1\u30a4\u30eb\u60c5\u5831", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2017-08-01"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "s1-ln234847841682381206-1939656818Hwf-2035235115IdV16389160123484784PDF_HI0001.pdf", "filesize": [{"value": "1.2 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 1200000.0, "url": {"label": "s1-ln234847841682381206-1939656818Hwf-2035235115IdV16389160123484784PDF_HI0001.pdf \u30d5\u30a1\u30a4\u30eb\u516c\u958b\uff1a2017/08/01", "url": "https://nagoya.repo.nii.ac.jp/record/23126/files/s1-ln234847841682381206-1939656818Hwf-2035235115IdV16389160123484784PDF_HI0001.pdf"}, "version_id": "296797fd-c86c-4c05-a3ce-25166142d2ee"}]}, "item_keyword": {"attribute_name": "\u30ad\u30fc\u30ef\u30fc\u30c9", "attribute_value_mlt": [{"subitem_subject": "immune suppression", "subitem_subject_scheme": "Other"}, {"subitem_subject": "immune checkpoint inhibitors", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Treg-targeted therapy", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "\u8a00\u8a9e", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "\u8cc7\u6e90\u30bf\u30a4\u30d7", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Roles of regulatory T cells in cancer immunity", "item_titles": {"attribute_name": "\u30bf\u30a4\u30c8\u30eb", "attribute_value_mlt": [{"subitem_title": "Roles of regulatory T cells in cancer immunity"}]}, "item_type_id": "10", "owner": "1", "path": ["499/500/501"], "permalink_uri": "http://hdl.handle.net/2237/25320", "pubdate": {"attribute_name": "\u516c\u958b\u65e5", "attribute_value": "2017-01-05"}, "publish_date": "2017-01-05", "publish_status": "0", "recid": "23126", "relation": {}, "relation_version_is_last": true, "title": ["Roles of regulatory T cells in cancer immunity"], "weko_shared_id": null}
  1. C100 医学部/医学系研究科
  2. C100a 雑誌掲載論文
  3. 学術雑誌

Roles of regulatory T cells in cancer immunity

http://hdl.handle.net/2237/25320
43abe488-2a8b-473c-9344-978055ab1b1d
名前 / ファイル ライセンス アクション
s1-ln234847841682381206-1939656818Hwf-2035235115IdV16389160123484784PDF_HI0001.pdf s1-ln234847841682381206-1939656818Hwf-2035235115IdV16389160123484784PDF_HI0001.pdf ファイル公開:2017/08/01 (1.2 MB)
Item type 学術雑誌論文 / Journal Article(1)
公開日 2017-01-05
タイトル
タイトル Roles of regulatory T cells in cancer immunity
著者 Takeuchi, Yoshiko

× Takeuchi, Yoshiko

WEKO 68545

Takeuchi, Yoshiko

Search repository
Nishikawa, Hiroyoshi

× Nishikawa, Hiroyoshi

WEKO 68546

Nishikawa, Hiroyoshi

Search repository
権利
権利情報 This is a pre-copyedited, author-produced version of an article accepted for publication in [International Immunology] following peer review. The version of record [International Immunology. v.28, n.8, 2016, p.401-409] is available online at: http://doi.org/10.1093/intimm/dxw025.
キーワード
主題Scheme Other
主題 immune suppression
キーワード
主題Scheme Other
主題 immune checkpoint inhibitors
キーワード
主題Scheme Other
主題 Treg-targeted therapy
抄録
内容記述 CD4+ regulatory T cells (Tregs) expressing the transcription factor FoxP3 are highly immune suppressive and play central roles in the maintenance of self-tolerance and immune homeostasis, yet in malignant tumors they promote tumor progression by suppressing effective antitumor immunity. Indeed, higher infiltration by Tregs is observed in tumor tissues, and their depletion augments antitumor immune responses in animal models. Additionally, increased numbers of Tregs and, in particular, decreased ratios of CD8+ T cells to Tregs among tumor-infiltrating lymphocytes are correlated with poor prognosis in various types of human cancers. The recent success of cancer immunotherapy represented by immune checkpoint blockade has provided a new insight in cancer treatment, yet more than half of the treated patients did not experience clinical benefits. Identifying biomarkers that predict clinical responses and developing novel immunotherapies are therefore urgently required. Cancer patients whose tumors contain a large number of neoantigens stemming from gene mutations, which have not been previously recognized by the immune system, provoke strong antitumor T-cell responses associated with clinical responses following immune checkpoint blockade, depending on the resistance to Treg-mediated suppression. Thus, integration of a strategy restricting Treg-mediated immune suppression may expand the therapeutic spectrum of cancer immunotherapy towards patients with a lower number of neoantigens. In this review, we address the current understanding of Treg-mediated immune suppressive mechanisms in cancer, the involvement of Tregs in cancer immunotherapy, and strategies for effective and tolerable Treg-targeted therapy.
内容記述タイプ Abstract
出版者
出版者 Oxford University Press
言語
言語 eng
資源タイプ
資源タイプresource http://purl.org/coar/resource_type/c_6501
タイプ journal article
ISSN
収録物識別子タイプ ISSN
収録物識別子 0953-8178
書誌情報 International Immunology

巻 28, 号 8, p. 401-409, 発行日 2016-08
著者版フラグ
値 author
URI
識別子 http://doi.org/10.1093/intimm/dxw025
識別子タイプ DOI
URI
識別子 http://hdl.handle.net/2237/25320
識別子タイプ HDL
戻る
0
views
See details
Views

Versions

Ver.1 2021-03-01 14:40:59.816631
Show All versions

Share

Mendeley CiteULike Twitter Facebook Print Addthis

Cite as

Export

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by CERN Data Centre & Invenio


Powered by CERN Data Centre & Invenio